Bio-Techne earns exceptional free cash flow at 274% of net income, holds a Piotroski financial health score of 8 out of 9, and maintains high gross margins — but the Protein Sciences segment represents 72% of revenue, top-line revenue has declined 2% year-over-year, and the stock is trading above its resistance take-profit target with negative asymmetry.
Thesis pillars
- Protein Sciences Segment Concentration↓Deteriorating
- Exceptional Cash Conversion Quality→Stable
- Revenue Decline With Strong Cash Flow→Stable
- +1 more pillar — see the Why tab for full reasoning
Bio-Techne Corp (TECH) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $72.59, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining.
Bio-Techne develops, manufactures, and sells life science reagents, instruments, and diagnostics products through its Protein Sciences segment (R&D Systems, Novus Biologicals, ProteinSimple) and Diagnostics and Spatial Biology segment (ACD, Exosome Diagnostics, Asuragen).... Read more
Hold if already holding. Not a fresh buy at $72.59, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Bio-Techne Corp
About Bio-Techne Corp
Bio-Techne's Protein Sciences segment — built on R&D Systems, Tocris, Novus Biologicals, and ProteinSimple brands — generated approximately 72% of net sales in fiscal 2025, while its Diagnostics and Spatial Biology segment, anchored by Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen, contributed about 28%. The company manufactures most of its hundreds of thousands of products itself across sites in North America, the U.K., Canada, Switzerland, and China, and employed approximately 3,100 people, with about 800 outside the United States.
Bio-Techne sells most Protein Sciences products directly to academic and industry researchers, pharmaceutical and biotech companies, and contract research organizations in North America, Europe, and China, supplemented by a distribution agreement with Thermo Fisher Scientific and third-party distributors in China, Japan, and Eastern Europe. Its Diagnostics and Spatial Biology segment reaches researchers directly in the same core geographies and through distributors elsewhere, while most Diagnostic Reagents division sales run through OEM agreements with instrument manufacturers and its ExosomeDx Prostate test reaches patients through physicians under the company's CLIA-certified Massachusetts laboratory. The company has licensed its ExoTRU kidney transplant rejection test exclusively to Thermo Fisher Scientific and holds a 19.9% stake in Wilson Wolf Corporation, a cell-culture device maker for cell-based therapies, with plans to acquire the remainder by the end of calendar 2027. Bio-Techne introduced more than 400 new products in fiscal 2025 and held roughly 1,340 granted patents as of June 30, 2025, protecting innovation in its Analytical Solutions and Spatial Biology divisions while relying more on trade secrets within Reagent Solutions.
Show full overview
Bio-Techne runs two different regulatory pathways side by side within its diagnostics business: the ExoDx Prostate test reaches patients as a lab-developed test regulated under CLIA through the company's Massachusetts-certified laboratory rather than through FDA clearance, while most Diagnostic Reagents division products are sold on an OEM basis to instrument manufacturers and are FDA-cleared. That split means a change in how regulators treat lab-developed tests specifically could reshape the economics of the Molecular Diagnostics division without touching the FDA-cleared Diagnostic Reagents business at all, a distinction worth tracking separately within the Diagnostics and Spatial Biology segment rather than as a single regulatory bucket.
See also: Healthcare · Biotechnology
From Bio-Techne Corp's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-25Recent Developments — Bio-Techne Corp
Latest news
- NEWS Dow drops over 1,100 points as sinking tech stocks combine with jumping oil prices to drag markets down - Fortune — Fortune negative
- NEWS Tech stock hits 52-week high at 72.17 USD By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Some tech shares are plunging - what does that mean for the AI revolution? - BBC — BBC negative
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - finance.yahoo.com — finance.yahoo.com neutral
Generated 2026-09-25T20:52:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductProtein Sciences segment72%10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2025.'
- MEDIUMProductDiagnostics and Spatial Biology segment28%10-K Item 1: 'The Diagnostics and Spatial Biology segment, representing approximately 28% of our net revenues in fiscal 2025, includes three divisions'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $72.59, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $83.48 (+15.0%), stop $72.23 (−0.5%), A.R:R -1.0:1. Score 5.0/10, moderate confidence.
Take-profit target: $83.48 (-15.2% upside). Target $83.48 (+15.0%), stop $72.23 (−0.5%), A.R:R -1.0:1. Stop-loss: $72.23.
Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.1% away).
Bio-Techne Corp trades at a P/E of 62.6 (forward 31.5). TrendMatrix value score: 3.0/10. Verdict: Hold.
22 analysts cover TECH with a consensus score of 3.5/5. Average price target: $71.
What does Bio-Techne Corp do?Bio-Techne develops, manufactures, and sells life science reagents, instruments, and diagnostics products through its...
Bio-Techne develops, manufactures, and sells life science reagents, instruments, and diagnostics products through its Protein Sciences segment (R&D Systems, Novus Biologicals, ProteinSimple) and Diagnostics and Spatial Biology segment (ACD, Exosome Diagnostics, Asuragen). Protein Sciences generated about 72% of fiscal 2025 net sales and Diagnostics and Spatial Biology about 28%, with no customer topping 10% of either segment's sales.